BMS-986020 (BMS986020, AM152) is a potent, selective, orally available LPA1 receptor antagonist with Kb value of 6.7 nM.
BMS-986020 has been reported to have an IC50 value < 300 nM for human LPA1, whereas that for LPA3 was about 1-10 μM.
BMS-986020 shows potential for lung fibrosis and psoriasis, against both acute and sub-acute injuries after ischemic stroke by employing a mouse model with transient middle cerebral artery occlusion (tMCAO).
